NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

基因治療的腺相關病毒(AAV)載體:流行病學考察 (∼2030年)

Adeno-Associated Virus (AAV) Vectors in Gene Therapy - Epidemiology Insight - 2030

出版商 DelveInsight Business Research LLP 商品編碼 966747
出版日期 按訂單生產 內容資訊 英文 100 Pages
商品交期: 10個工作天內
價格
基因治療的腺相關病毒(AAV)載體:流行病學考察 (∼2030年) Adeno-Associated Virus (AAV) Vectors in Gene Therapy - Epidemiology Insight - 2030
出版日期: 按訂單生產內容資訊: 英文 100 Pages
簡介

本報告提供美國,歐洲5國(德國,西班牙,義大利,法國,英國)以及日本等7個主要市場基因治療的腺相關病毒(AAV)載體市場相關詳細說明,提供疾病的背景和概要,未滿足需求,各國的流行病學,治療方法等相關資訊。

目錄

第1章 主要考察

第2章 摘要整理

第3章 基因治療的腺相關病毒(AAV)載體:疾病的背景和概要

  • 簡介
  • 徵兆與症狀
  • 病理學
  • 危險因素
  • 診斷

第4章 患者治療過程

第5章 流行病學和患者人口

  • 流行病學的主要調查結果
  • 前提條件與理論的根據:主要7個國家
  • 流行病學方案:主要7個國家
    • 主要7個國家的基因治療的腺相關病毒(AAV)載體的流行病學方案
  • 美國的流行病學
    • 美國的基因治療的腺相關病毒(AAV)載體的流行病學方案
  • 歐洲5國的流行病學:各國
    • 德國的流行病學
    • 法國的流行病學
    • 義大利的流行病學
    • 西班牙的流行病學
    • 英國的流行病學
  • 日本的流行病學
    • 日本的基因治療的腺相關病毒(AAV)載體的流行病學方案

第6章 治療流程,目前治療,及醫療行為

  • 基因治療的腺相關病毒(AAV)載體的治療和管理
  • 基因治療的腺相關病毒(AAV)載體的治療流程

第7章 KOL的見解

第8章 未滿足需求

第9章 附錄

  • 參考文獻
  • 報告的調查手法

第10章 DelveInsight的服務內容

第11章 免責聲明

第12章 關於DelveInsight

目錄
Product Code: DIEI1022

DelveInsight's 'Adeno-Associated Virus (AAV) Vectors in Gene Therapy - Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical and forecasted Adeno-Associated Virus (AAV) Vectors in Gene Therapy epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Adeno-Associated Virus (AAV) Vectors in Gene Therapy Understanding

The DelveInsight Adeno-Associated Virus (AAV) Vectors in Gene Therapy epidemiology report gives a thorough understanding of the Adeno-Associated Virus (AAV) Vectors in Gene Therapy by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Adeno-Associated Virus (AAV) Vectors in Gene Therapy in the US, Europe, and Japan. The report covers the detailed information of the Adeno-Associated Virus (AAV) Vectors in Gene Therapy epidemiology scenario in seven major countries (US, EU5, and Japan).

Adeno-Associated Virus (AAV) Vectors in Gene Therapy Epidemiology Perspective by DelveInsight

The Adeno-Associated Virus (AAV) Vectors in Gene Therapy epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Adeno-Associated Virus (AAV) Vectors in Gene Therapy epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Adeno-Associated Virus (AAV) Vectors in Gene Therapy epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2017 to 2030. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Adeno-Associated Virus (AAV) Vectors in Gene Therapy Detailed Epidemiology Segmentation

The Adeno-Associated Virus (AAV) Vectors in Gene Therapy epidemiology covered in the report provides historical as well as forecasted Adeno-Associated Virus (AAV) Vectors in Gene Therapy epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom) and Japan from 2017 to 2030.

The DelveInsight Adeno-Associated Virus (AAV) Vectors in Gene Therapy report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

Scope of the Report:

  • The Adeno-Associated Virus (AAV) Vectors in Gene Therapy report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • The Adeno-Associated Virus (AAV) Vectors in Gene Therapy Epidemiology Report and Model provide an overview of the risk factors and global trends of Adeno-Associated Virus (AAV) Vectors in Gene Therapy in the seven major markets (7MM:US, France, Germany, Italy, Spain, UK, and Japan)
  • The report provides insight about the historical and forecasted patient pool of Adeno-Associated Virus (AAV) Vectors in Gene Therapy in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population
  • The report assesses the disease risk and burden and highlights the unmet needs of Adeno-Associated Virus (AAV) Vectors in Gene Therapy
  • The report provides the segmentation of the Adeno-Associated Virus (AAV) Vectors in Gene Therapy epidemiology

Report Highlights:

  • 11-Year Forecast of Adeno-Associated Virus (AAV) Vectors in Gene Therapy epidemiology
  • 7MM Coverage
  • Total Cases of Adeno-Associated Virus (AAV) Vectors in Gene Therapy
  • Total Cases of Adeno-Associated Virus (AAV) Vectors in Gene Therapy according to segmentation
  • Diagnosed cases of Adeno-Associated Virus (AAV) Vectors in Gene Therapy

KOL- Views

We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Adeno-Associated Virus (AAV) Vectors in Gene Therapy?
  • What are the key findings pertaining to the Adeno-Associated Virus (AAV) Vectors in Gene Therapy epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017-2030)?
  • What would be the total number of patients of Adeno-Associated Virus (AAV) Vectors in Gene Therapy across the 7MM during the forecast period (2017-2030)?
  • Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017-2030)?
  • At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017-2030)?
  • What is the disease risk, burden and unmet needs of the Adeno-Associated Virus (AAV) Vectors in Gene Therapy?
  • What are the currently available treatments of Adeno-Associated Virus (AAV) Vectors in Gene Therapy?

Reasons to buy:

  • The Adeno-Associated Virus (AAV) Vectors in Gene Therapy Epidemiology report will allow the user to -
  • Develop business strategies by understanding the trends shaping and driving the global Adeno-Associated Virus (AAV) Vectors in Gene Therapy market
  • Quantify patient populations in the global Adeno-Associated Virus (AAV) Vectors in Gene Therapy market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Adeno-Associated Virus (AAV) Vectors in Gene Therapy therapeutics in each of the markets covered
  • Understand the magnitude of Adeno-Associated Virus (AAV) Vectors in Gene Therapy population by its epidemiology
  • The Adeno-Associated Virus (AAV) Vectors in Gene Therapy Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

Table of Contents

1. Key Insights

2. Executive Summary of Adeno-Associated Virus (AAV) Vectors in Gene Therapy

3. Adeno-Associated Virus (AAV) Vectors in Gene Therapy : Disease Background and Overview

  • 3.1. Introduction
  • 3.2. Sign and Symptoms
  • 3.3. Pathophysiology
  • 3.4. Risk Factors
  • 3.5. Diagnosis

4. Patient Journey

5. Epidemiology and Patient Population

  • 5.1. Epidemiology Key Findings
  • 5.2. Assumptions and Rationale: 7MM
  • 5.3. Epidemiology Scenario: 7MM
    • 5.3.1. Adeno-Associated Virus (AAV) Vectors in Gene Therapy Epidemiology Scenario in the 7MM (2017- 2030)
  • 5.4. United States Epidemiology
    • 5.4.1. Adeno-Associated Virus (AAV) Vectors in Gene Therapy Epidemiology Scenario in the United States (2017- 2030)
  • 5.5. EU-5 Country-wise Epidemiology
    • 5.5.1. Germany Epidemiology
      • 5.5.1.1. Adeno-Associated Virus (AAV) Vectors in Gene Therapy Epidemiology Scenario in Germany (2017- 2030)
    • 5.5.2. France Epidemiology
      • 5.5.2.1. Adeno-Associated Virus (AAV) Vectors in Gene Therapy Epidemiology Scenario in France (2017- 2030)
    • 5.5.3. Italy Epidemiology
      • 5.5.3.1. Adeno-Associated Virus (AAV) Vectors in Gene Therapy Epidemiology Scenario in Italy (2017- 2030)
    • 5.5.4. Spain Epidemiology
      • 5.5.4.1. Adeno-Associated Virus (AAV) Vectors in Gene Therapy Epidemiology Scenario in Spain (2017- 2030)
    • 5.5.5. United Kingdom Epidemiology
      • 5.5.5.1. Adeno-Associated Virus (AAV) Vectors in Gene Therapy Epidemiology Scenario in the United Kingdom (2017-2030)
  • 5.6. Japan Epidemiology
    • 5.6.1. Adeno-Associated Virus (AAV) Vectors in Gene Therapy Epidemiology Scenario in Japan (2017- 2030)

6. Treatment Algorithm, Current Treatment, and Medical Practices

  • 6.1. Adeno-Associated Virus (AAV) Vectors in Gene Therapy Treatment and Management
  • 6.2. Adeno-Associated Virus (AAV) Vectors in Gene Therapy Treatment Algorithm

7. KOL Views

8. Unmet Needs

9. Appendix

  • 9.1. Bibliography
  • 9.2. Report Methodology

10. DelveInsight Capabilities

11. Disclaimer

12. About DelveInsight

The table of contents is not exhaustive; will be provided in the final report

List of Tables

  • Table 1: Adeno-Associated Virus (AAV) Vectors in Gene Therapy Epidemiology in 7MM (2017-2030)
  • Table 2: Adeno-Associated Virus (AAV) Vectors in Gene Therapy Diagnosed and Treatable Cases in 7MM (2017-2030)
  • Table 3: Adeno-Associated Virus (AAV) Vectors in Gene Therapy Epidemiology in the United States (2017-2030)
  • Table 4: Adeno-Associated Virus (AAV) Vectors in Gene Therapy Diagnosed and Treatable Cases in the United States (2017-2030)
  • Table 5: Adeno-Associated Virus (AAV) Vectors in Gene Therapy Epidemiology in Germany (2017-2030)
  • Table 6: Adeno-Associated Virus (AAV) Vectors in Gene Therapy Diagnosed and Treatable Cases in Germany (2017-2030)
  • Table 7: Adeno-Associated Virus (AAV) Vectors in Gene Therapy Epidemiology in France (2017-2030)
  • Table 8: Adeno-Associated Virus (AAV) Vectors in Gene Therapy Diagnosed and Treatable Cases in France (2017-2030)
  • Table 9: Adeno-Associated Virus (AAV) Vectors in Gene Therapy Epidemiology in Italy (2017-2030)
  • Table 10: Adeno-Associated Virus (AAV) Vectors in Gene Therapy Diagnosed and Treatable Cases in Italy (2017-2030)
  • Table 11: Adeno-Associated Virus (AAV) Vectors in Gene Therapy Epidemiology in Spain (2017-2030)
  • Table 12: Adeno-Associated Virus (AAV) Vectors in Gene Therapy Diagnosed and Treatable Cases in Spain (2017-2030)
  • Table 13: Adeno-Associated Virus (AAV) Vectors in Gene Therapy Epidemiology in the United Kingdom (2017-2030)
  • Table 14: Adeno-Associated Virus (AAV) Vectors in Gene Therapy Diagnosed and Treatable Cases in the United Kingdom (2017-2030)
  • Table 15: Adeno-Associated Virus (AAV) Vectors in Gene Therapy Epidemiology in Japan (2017-2030)
  • Table 16: Adeno-Associated Virus (AAV) Vectors in Gene Therapy Diagnosed and Treatable Cases in Japan (2017-2030)

List of Figures

  • Figure 1: Adeno-Associated Virus (AAV) Vectors in Gene Therapy Epidemiology in 7MM (2017-2030)
  • Figure 2: Adeno-Associated Virus (AAV) Vectors in Gene Therapy Diagnosed and Treatable Cases in 7MM (2017-2030)
  • Figure 3: Adeno-Associated Virus (AAV) Vectors in Gene Therapy Epidemiology in the United States (2017-2030)
  • Figure 4: Adeno-Associated Virus (AAV) Vectors in Gene Therapy Diagnosed and Treatable Cases in the United States (2017-2030)
  • Figure 5: Adeno-Associated Virus (AAV) Vectors in Gene Therapy Epidemiology in Germany (2017-2030)
  • Figure 6: Adeno-Associated Virus (AAV) Vectors in Gene Therapy Diagnosed and Treatable Cases in Germany (2017-2030)
  • Figure 7: Adeno-Associated Virus (AAV) Vectors in Gene Therapy Epidemiology in France (2017-2030)
  • Figure 8: Adeno-Associated Virus (AAV) Vectors in Gene Therapy Diagnosed and Treatable Cases in France (2017-2030)
  • Figure 9: Adeno-Associated Virus (AAV) Vectors in Gene Therapy Epidemiology in Italy (2017-2030)
  • Figure 10: Adeno-Associated Virus (AAV) Vectors in Gene Therapy Diagnosed and Treatable Cases in Italy (2017-2030)
  • Figure 11: Adeno-Associated Virus (AAV) Vectors in Gene Therapy Epidemiology in Spain (2017-2030)
  • Figure 12: Adeno-Associated Virus (AAV) Vectors in Gene Therapy Diagnosed and Treatable Cases in Spain (2017-2030)
  • Figure 13: Adeno-Associated Virus (AAV) Vectors in Gene Therapy Epidemiology in the United Kingdom (2017-2030)
  • Figure 14: Adeno-Associated Virus (AAV) Vectors in Gene Therapy Diagnosed and Treatable Cases in the United Kingdom (2017-2030)
  • Figure 15: Adeno-Associated Virus (AAV) Vectors in Gene Therapy Epidemiology in Japan (2017-2030)
  • Figure 16: Adeno-Associated Virus (AAV) Vectors in Gene Therapy Diagnosed and Treatable Cases in Japan (2017-2030)

The table of contents is not exhaustive; will be provided in the final report